BioSpace News Archive

Bicycle Therapeutics plc, a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced that management will participate in the following investor conferences in June.

The Bruker Applied Mass Spectrometry Division is showcasing some of its latest innovations at ASMS 2024.

Genethon, a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association, provided updates in its latest Newsletter on results of its gene therapy clinical trials for Duchenne Muscular Dystrophy and advances in gene therapies for limb-girdle muscular dystrophies by its spinoff Atamyo Therapeutics.

Bio-Path Holdings, Inc. presented interim results from the Company’s Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia in an oral presentation at the American Society of Clinical Oncology Annual Meeting, on June 1, 2024 in Chicago, IL.

Kraig Biocraft Laboratories, Inc., announces that Kraig Labs is now in production with its BAM-1 recombinant spider silk hybrids.

Century Therapeutics today announced a poster presentation highlighting interim results from the ongoing Phase 1 ELiPSE-1 study evaluating CNTY-101 in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) at the American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31 – June 4, 2024 in Chicago, Illinois.

Axsome Therapeutics, Inc. announced today it is supporting Alzheimer’s & Brain Awareness Month this June.

Alkermes plc announced new data from the full narcolepsy type 1 cohort of a phase 1b, proof-of-concept study evaluating ALKS 2680, the company’s novel, investigational, oral orexin 2 receptor agonist in development as a once-daily treatment for narcolepsy.

BPGbio, Inc. today announced that seasoned biotech leader and venture capital investor, Scott Minick, has been elected to its Board of Directors.

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that results from the Company’s MOTION pivotal Phase 3 study of vimseltinib in patients with TGCT are being highlighted in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.